Angina inestable

NGC banner

Guideline Summary NGC-5906
Guideline Title ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-Elevation myocardial infarction. Bibliographic Source(s) Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK,Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee, American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association ofCardiovascular and Pulmonary Rehabilitation, Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology. J Am Coll Cardiol 2007 Aug 14;50(7):e1-e157. [957 references] PubMed Guideline Status This is the most current release of the guideline. Thisguideline updates a previous version: American College of Cardiology Foundation, American Heart Association. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Bethesda (MD): American College of Cardiology Foundation (ACCF);2002 Mar. 95 p. FDA Warning/Regulatory Alert Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released. : The U.S. Food and Drug Administration (FDA) notified healthcare   November 9, 2011 – Trilipix (fenofibric acid)  professionals the cholesterol-lowering medicine Trilipix (fenofibricacid) may not lower a patient's risk of having a heart attack or stroke. FDA reviewed the data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial. The ACCORD Lipid trial found no significant difference in the risk of experiencing a major adverse cardiac event between the group treated with fenofibrate plus simvastatin compared with simvastatin alone. Information from thetrial has been added to the Important Limitations of Use and Warnings and Precautions sections of the Trilipix physician label and to the patient Medication Guide.
l

: The U.S. Food and Drug Administration (FDA) notified healthcare   June 8, 2011 – Zocor (simvastatin)  professionals that it is recommending limiting the use of the highest approved dose of the cholesterol-lowering medicationsimvastatin (80 mg) because of increased risk of muscle damage. FDA is requiring changes to the simvastatin label to add new contraindications (should not be used with certain medications) and dose limitations for using simvastatin with certain medicines.
l

Scope
Disease/Condition(s) l   Coronary artery disease 
l l

  Unstable angina    Non-ST-segment elevation myocardial infarctionGuideline Category Diagnosis Evaluation Management Prevention Risk Assessment Treatment Clinical Specialty Cardiology Emergency Medicine Family Practice Geriatrics Internal Medicine Thoracic Surgery Intended Users

Emergency Medicine Family Practice Geriatrics Internal Medicine Thoracic Surgery Intended Users Health Care Providers Physicians Guideline Objective(s) l  To address the diagnosis and management of patients with unstable angina (UA) and the closely related condition of non-ST-elevation myocardial infarction (NSTEMI)   To assist both cardiovascular specialists and nonspecialists in the proper evaluation and management of patients  with an acute onset of symptoms suggestive of these conditions
l

  To provide recommendations and supporting evidence for the continued management...